Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06NXK
|
||||
| Former ID |
DNC010924
|
||||
| Drug Name |
(R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H20N2
|
||||
| Canonical SMILES |
CC1CCCN1CCC2=CC3=C(C=C2)N=CC=C3
|
||||
| InChI |
1S/C16H20N2/c1-13-4-3-10-18(13)11-8-14-6-7-16-15(12-14)5-2-9-17-16/h2,5-7,9,12-13H,3-4,8,10-11H2,1H3/t13-/m1/s1
|
||||
| InChIKey |
HUQYUKHHFHNJRR-CYBMUJFWSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Potassium voltage-gated channel subfamily H member 2 | Target Info | Inhibitor | [1] | |
| Histamine H3 receptor | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Voltage gated Potassium channelsR-HSA-390650:Histamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Hematopoietic Stem Cell Differentiation | |||||
| Potassium ChannelsWP727:Monoamine Transport | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2010 Jun 1;20(11):3295-300. Epub 2010 Apr 18.In vitro studies on a class of quinoline containing histamine H3 antagonists. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.